Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716975 · ClinicalTrials.gov registry record · Phase 3
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Phase 3 study of Schizophrenia and Impaired Cognition, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 767
- Enrollment target
- 20
- Study locations
NCT01716975: Completed Phase 3 study of Schizophrenia and Impaired Cognition, sponsored by FORUM Pharmaceuticals.
NCT01716975 is a Phase 3 study of Schizophrenia and Impaired Cognition that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 767 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (253% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01716975, a Phase 3 study of Schizophrenia and Impaired Cognition, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 767 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EVP-6124
Study Locations (20)
California
- - Cerritos
- - Chino
- - Costa Mesa
- - Garden Grove
- - Glendale
- - Norwalk
- - Oakland
- - Oakland Park
- - Oceanside
- - Riverside
- - San Diego
- - San Gabriel
- - Santa Ana
- - Sherman Oaks
Florida
- - Bradenton
- - Miami
- - Miami Springs
Arizona
- - Phoenixville
Arkansas
- - Little Rock
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
What the finished NCT01716975 record still lists
NCT01716975 is an interventional study that assigns participants to a tested intervention. The registered 767 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (253% higher).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01716975 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01716975 about?
NCT01716975 is a clinical study titled "Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy". The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
What is the current status of trial NCT01716975?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 767 participants. The study started on 2012-10. Estimated completion is 2016-02.
What conditions does trial NCT01716975 study?
This clinical trial studies the following conditions: Schizophrenia, Impaired Cognition.
What interventions are being tested in trial NCT01716975?
The interventions under investigation include: Placebo (DRUG), EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01716975?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01716975 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01716975's enrollment target sits among peer trials
767 15th of 315 higher than 301 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia